Billionaire, Point 72’s Steve Cohen, Continues to Support Psychedelic Research.

Cohen Psychedelic Research & Health Initiative Cohen Foundation Awards $5 Million for MDMA Therapy Approval Millions...

Hepion Pharmaceuticals (HEPA) Announces Passing of Key Safety Milestone in Phase 2b ‘ASCEND-NASH’ Trial...

Completion of Enrollment Remains on Track for Q1, 2024 "While we recently had fireworks, we could be looking at...

Psycheceutical’s (BWVI) NeuroDirect™ Ketamine can Help Alleviate Headaches and Migraines Within Minutes, With no...

Photo MAPS Founder Rick Doblin visits Psycheceutical's Chief Visionary Officer Mike 'Zappy' Zapolin, CEO Chad Harman at the company's lab and tests...

Psycheceutical Bioscience (BWVI) Secures Funding for Clinical Trials

Psycheceutical Secures Funding for Clinical Trials of NeuroDirect™ Ketamine Topical to Treat PTSD. Company raises $1.3M USD convertible note...
Pressure Bioscience, Biotech Stock Review, Roland Rick Perry

Pressure Bioscience (PBIO) Meets Ohio State University. Pressure Testing on Food and Beverages.

OHIO STATE INSTALLS, COMMISSIONS NEW PILOT-SCALE ULTRA-SHEAR TECHNOLOGY EQUIPMENT FOR LIQUID FOODS AND BEVERAGES PROCESSING Past News From Ohio...

Adding Pressure BioSciences (PBIO) $0.80 to Watch List.

Long Time Coming, Pressure Bio Reaches Turning Point. Science Finally Meets Revenues. Photo Ric Schumacher CEO

CEO Interview: Ric Schumacher Pressure Bioscience (PBIO).

https://youtu.be/a8d1bawmMQk RELATED: Adding Pressure BioSciences (PBIO) $0.80 to Watch...
pRESSURE bIOSCIENCE

Pressure BioSciences (PBIO) Receives $1.5M Contract for UltraShear Nanoemulsified CBD.

CBD Supply MD, a Leading Maryland-Based CBD Retailer, to Introduce PBIO's UltraShear Processed, Best-in-Class Nanoemulsified CBD Products Across the Multi-State Mid-Atlantic Region

Asia-Pacific: A Region of Stability Amidst Economic Uncertainty

Contrary to the Western markets, there is a growing consensus that the Asia Pacific is emerging as a relatively safe harbour in...

Hepion (HEPA) Back in the Spotlight, Gains 230% in May.

Hepion (HEPA) Phase 2 ‘ALTITUDE-NASH’ Trial Achieves Primary and Secondary Endpoints, Including Improvement in Liver Function and...

Latest article

Nine Page Summary Report on GeoVax (GOVX)

This is a great long-term story. We’re telling you. (March 2024) When we finished writing our earlier...

GeoVax (GOVX) Provides First Half 2024 Business Update.

Award of BARDA Project NextGen contract represents a significant milestone event; Total value...

Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.

Can You Imagine Selling Solgenix at $2.00 yesterday. And to be honest, news wasn't all that big - such...